Trial Profile
A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Ad26.COV2 S (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 05 Jan 2023 Results assessing safety, reactogenicity, and immunogenicity of a 2-month homologous booster regimen of Ad26.COV2.S in Japanese adults published in the Vaccine
- 23 Nov 2021 Status changed from active, no longer recruiting to completed.
- 22 Dec 2020 Status changed from recruiting to active, no longer recruiting.